sotatercept
sotatercept: sourced relationships with 1 company · 9 clinical trials tracked.
sotatercept evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could sotatercept → XLRN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ACCELERON PHARMA INC (XLRN) Pulmonary Arterial Hypertension; Hypertension, Pulmonary | Phase 3 |
Clinical Trial Registry Records (9)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sotatercept in Adults With Combined Postcapillary and Precapillary Pulmonary Hypertension (CpcPH) and Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary endpoint: Time to Clinical Worsening (TTCW)
A Phase 4, Prospective, Open-label, Single-Arm Study to Evaluate the Safety of Sotatercept in Adults With Pulmonary Arterial Hypertension (PAH) in India
Primary endpoint: Number of participants who experience an adverse event (AE)
A Phase 2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotatercept (MK-7962) in Japanese Children From 1 to Less Than 18 Years of Age With PAH on Standard of Care.
Primary endpoint: Number of Participants With One or More Adverse Events
A Single-arm, Open-label Phase IV Study to Evaluate the Effectiveness of Sotatercept in Improving Pulmonary Vascular Recruitment in Patients With Pulmonary Arterial Hypertension (PAH)
Primary endpoint: Lung diffusing capacity
A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
Primary endpoint: Median Time to Clinical Worsening
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary endpoint: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality
Primary endpoint: Time to First Confirmed Morbidity or Mortality Event
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)
Frequently asked questions
Which companies have sourced relationships with sotatercept?
sotatercept has dated SEC/FDA relationship records for ACCELERON PHARMA INC.
How many clinical trials involve sotatercept?
BioSniper tracks 9 clinical trials involving sotatercept.